Identifying SARS-CoV-2 Plasma Donors: An Alternative Assay
Identifying suitable COVID-19 convalescent plasma donors using a different approach
Olivia Gaskill | | Quick Read
Convalescent plasma therapy is under consideration for the treatment of COVID-19 patients, but finding suitable donors by measuring SARS-CoV-2 virus-neutralizing (VN) antibodies in the blood presents a challenge. The technique is complicated, labor-intensive, and restricted to biosafety level 3 laboratories. Researchers at the University of Texas at Austin and Houston Methodist recognized the need for a different approach and used accessible, easy-to-use ELISA to measure the relationship between anti-spike ectodomain (ECD), anti-receptor binding domain (RBD) IgG titers, and SARS-CoV-2 VN titers (1).
Testing 2,814 plasma samples from asymptomatic adults, they found a strong positive correlation between anti-RBD and anti-ECD IgG titers and VN antibody levels at or above the FDA-recommended levels recommended for COVID-19 convalescent plasma. As viable alternatives to VN titers, these assays could enable more widespread identification of suitable convalescent plasma donors.
Enjoy our FREE content!
Log in or register to gain full unlimited access to all content on the The Pathologist site. It’s FREE!
Or register now - it’s free!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Pathologist magazine
- E Salazar et al., J Clin Invest, [ePub ahead of print] (2020). PMID: 32910806.